Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells

Molecular Cancer

Volumn 8, Issue , 2009, Pages

  Sei, Shizuko ^a   Mussio, Jodie K ^a   Yang, Quan En ^a   Nagashima, Kunio ^a   Parchment, Ralph E ^a   Coffey, Matthew C ^b   Shoemaker, Robert H ^c   Tomaszewski, Joseph E ^d  

^a SAIC FREDERICK INC   (United States)

^b ONCOLYTICS BIOTECH INC   (Canada)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CELL DNA; CISPLATIN; GEMCITABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ONCOLYTIC REOVIRUS SEROTYPE 3 DEARING STRAIN; ONCOLYTIC VIRUS; PACLITAXEL; REOLYSIN; UNCLASSIFIED DRUG; VINBLASTINE; ANTINEOPLASTIC AGENT; CASPASE; DEOXYCYTIDINE; DRUG DERIVATIVE; RAS PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CELL KILLING; CONTROLLED STUDY; DNA CONTENT; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MITOSIS INHIBITION; MULTINUCLEAR CELL; ONCOLYTIC VIROTHERAPY; PROTEIN CLEAVAGE; VIRUS STRAIN; CELL CYCLE; CELL SURVIVAL; DRUG EFFECT; LUNG TUMOR; MAMMALIAN ORTHOREOVIRUS; METABOLISM; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; TUMOR CELL LINE; VIRION; VIROLOGY;

MAMMALIAN ORTHOREOVIRUS 3; ORTHOREOVIRUS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASES; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DRUG SYNERGISM; ENZYME ACTIVATION; HUMANS; LUNG NEOPLASMS; MAMMALIAN ORTHOREOVIRUS 3; ONCOLYTIC VIROTHERAPY; PACLITAXEL; POLY(ADP-RIBOSE) POLYMERASES; RAS PROTEINS; VINBLASTINE; VIRION;

EID: 68849111614     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-8-47     Document Type: Article

References (52)

1. Parato KA Senger D Forsyth PA Bell JC Recent progress in the battle between oncolytic viruses and tumours Nat Rev Cancer 2005, 5:965-976. 10.1038/nrc1750 16294217
2. Duncan MR Stanish SM Cox DC Differential sensitivity of normal and transformed human cells to reovirus infection J Virol 1978, 28:444-449. 354293 214572
3. Kilani RT Tamimi Y Hanel EG Wong KK Karmali S Lee PW Moore RB Selective reovirus killing of bladder cancer in a co-culture spheroid model Virus Res 2003, 93:1-12. 10.1016/S0168-1702(03)00045-5 12727337
4. Alain T Hirasawa K Pon KJ Nishikawa SG Urbanski SJ Auer Y Luider J Martin A Johnston RN Janowska-Wieczorek A Lee PW Kossakowska AE Reovirus therapy of lymphoid malignancies Blood 2002, 100:4146-4153. 10.1182/ blood-2002-02-0503 12393565
5. Coffey MC Strong JE Forsyth PA Lee PW Reovirus therapy of tumors with activated Ras pathway Science 1998, 282:1332-1334. 10.1126/ science.282.5392.1332 9812900
6. Etoh T Himeno Y Matsumoto T Aramaki M Kawano K Nishizono A Kitano S Oncolytic viral therapy for human pancreatic cancer cells by reovirus Clin Cancer Res 2003, 9:1218-1223. 12631628
7. Hirasawa K Nishikawa SG Norman KL Alain T Kossakowska A Lee PW Oncolytic reovirus against ovarian and colon cancer Cancer Res 2002, 62:1696-1701. 11912142
8. Norman KL Coffey MC Hirasawa K Demetrick DJ Nishikawa SG DiFrancesco LM Strong JE Lee PW Reovirus oncolysis of human breast cancer Hum Gene Ther 2002, 13:641-652. 10.1089/10430340252837233 11916487
9. Wilcox ME Yang W Senger D Rewcastle NB Morris DG Brasher PM Shi ZQ Johnston RN Nishikawa S Lee PW Forsyth PA Reovirus as an oncolytic agent against experimental human malignant gliomas J Natl Cancer Inst 2001, 93:903-912. 10.1093/jnci/93.12.903 11416111
10. Spicer JF Vidal L Pandha H Yap T White C Coffey M Thompson B Kaye S Harrington K De Bono J Final results of a phase I study of wild-type oncolytic reovirus administered intravenously to patients with advanced cancer ASCO Annual Meeting Proceedings Part I; June 1 - 5, 2007; Chicago, Illinois. J Clin Oncol 2007, 25:3572.
11. Strong JE Coffey MC Tang D Sabinin P Lee PW The molecular basis of viral oncolysis: Usurpation of the Ras signaling pathway by reovirus The EMBO journal 1998, 17:3351-3362. 1170673 9628872 10.1093/emboj/17.12.3351
12. Norman KL Hirasawa K Yang AD Shields MA Lee PW Reovirus oncolysis: The Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection Proc Natl Acad Sci USA 2004, 101:11099-11104. 503746 15263068 10.1073/pnas.0404310101
13. Ikediobi ON Davies H Bignell G Edkins S Stevens C O'Meara S Santarius T Avis T Barthorpe S Brackenbury L Buck G Butler A Clements J Cole J Dicks E Forbes S Gray K Halliday K Harrison R Hills K Hinton J Hunter C Jenkinson A Jones D Kosmidou V Lugg R Menzies A Mironenko T Parker A Perry J et al Mutation analysis of 24 known cancer genes in the NCI-60 cell line set Mol Cancer Ther 2006, 5:2606-2612. 2705832 17088437 10.1158/1535-7163.MCT-06-0433
14. Izquierdo MA Shoemaker RH Flens MJ Scheffer GL Wu L Prather TR Scheper RJ Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines Int J Cancer 1996, 65:230-237. 10.1002/ (SICI)1097-0215(19960117)65:2<230::AID-IJC17>3.0.CO;2-H 8567122
15. Chou TC Talalay P Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 1984, 22:27-55. 10.1016/0065-2571(84)90007-4 6382953
16. Chou T Relationships between inhibition constants and fractional inhibition in enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types and mechanisms of inhibition Mol Pharmacol 1974, 10:235-247. 4212316
17. Chou TC Talalay P Analysis of combined drug effects: A new look at a very old problem Trends Pharmacol Sci 1983, 4:450-454. 10.1016/ 0165-6147(83)90490-X
18. Clarke P Meintzer SM Spalding AC Johnson GL Tyler KL Caspase 8- dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus-infection Oncogene 2001, 20:6910-6919. 10.1038/ sj.onc.1204842 11687970
19. Poggioli GJ Keefer C Connolly JL Dermody TS Tyler KL Reovirusinduced G(2)/M cell cycle arrest requires sigma1s and occurs in the absence of apoptosis J Virol 2000, 74:9562-9570. 112387 11000227 10.1128/ JVI.74.20.9562-9570.2000
20. Twigger K Vidal L White CL De Bono JS Bhide S Coffey M Thompson B Vile RG Heinemann L Pandha HS Errington F Melcher AA Harrington KJ Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy Clin Cancer Res 2008, 14:912-923. 10.1158/1078-0432.CCR-07-1400 18245555
21. Weaver BA Cleveland DW Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death Cancer Cell 2005, 8:7-12. 10.1016/j.ccr.2005.06.011 16023594
22. Darmon AJ Nicholson DW Bleackley RC Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B Nature 1995, 377:446-448. 10.1038/377446a0 7566124
23. Edwards BK Brown ML Wingo PA Howe HL Ward E Ries LA Schrag D Jamison PM Jemal A Wu XC Friedman C Harlan L Warren J Anderson RN Pickle LW Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment J Natl Cancer Inst 2005, 97:1407-1427. 16204691
24. Parkin DM Bray F Ferlay J Pisani P Global cancer statistics, 2002 CA Cancer J Clin 2005, 55:74-108. 10.3322/canjclin.55.2.74 15761078
25. Chemotherapy for non-small cell lung cancer. Non-small Cell Lung Cancer Collaborative Group Cochrane Database Syst Rev 2000:CD002139. 10796867
26. van Houdt WJ Smakman N Wollenberg van den DJ Emmink BL Veenendaal LM van Diest PJ Hoeben RC Borel Rinkes IH Kranenburg O Transient infection of freshly isolated human colorectal tumor cells by reovirus T3D intermediate subviral particles Cancer Gene Ther 2008, 15:284-292. 10.1038/cgt.2008.2 18259212
27. Barton ES Forrest JC Connolly JL Chappell JD Liu Y Schnell FJ Nusrat A Parkos CA Dermody TS Junction adhesion molecule is a receptor for reovirus Cell 2001, 104:441-451. 10.1016/S0092-8674(01)00231-8 11239401
28. Strong JE Lee PW The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection J Virol 1996, 70:612-616. 189854 8523580
29. Chappell JD Gunn VL Wetzel JD Baer GS Dermody TS Mutations in type 3 reovirus that determine binding to sialic acid are contained in the fibrous tail domain of viral attachment protein sigma1 J Virol 1997, 71:1834-1841. 191253 9032313
30. Golden JW Linke J Schmechel S Thoemke K Schiff LA Addition of exogenous protease facilitates reovirus infection in many restrictive cells J Virol 2002, 76:7430-7443. 136394 12097555 10.1128/ JVI.76.15.7430-7443.2002
31. Alain T Kim TS Lun X Liacini A Schiff LA Senger DL Forsyth PA Proteolytic disassembly is a critical determinant for reovirus oncolysis Mol Ther 2007, 15:1512-1521. 10.1038/sj.mt.6300207 17519890
32. Toyoizumi T Mick R Abbas AE Kang EH Kaiser LR Molnar-Kimber KL Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer Hum Gene Ther 1999, 10:3013-3029. 10.1089/10430349950016410 10609661
33. Cinatl J Jr Cinatl J Michaelis M Kabickova H Kotchetkov R Vogel JU Doerr HW Klingebiel T Driever PH Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma Cancer Res 2003, 63:1508-1514. 12670897
34. Eisenberg DP Adusumilli PS Hendershott KJ Yu Z Mullerad M Chan MK Chou TC Fong Y 5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer J Gastrointest Surg 2005, 9:1068-1077. 1373688 16269377 10.1016/ j.gassur.2005.06.024
35. Yu DC Chen Y Dilley J Li Y Embry M Zhang H Nguyen N Amin P Oh J Henderson DR Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel Cancer Res 2001, 61:517-525. 11212244
36. Raki M Kanerva A Ristimaki A Desmond RA Chen DT Ranki T Sarkioja M Kangasniemi L Hemminki A Combination of gemcitabine and Ad5/3- Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer Gene Ther 2005, 12:1198-1205. 10.1038/ sj.gt.3302517 15800658
37. AbouEl Hassan MA Braam SR Kruyt FA Paclitaxel and vincristine potentiate adenoviral oncolysis that is associated with cell cycle and apoptosis modulation, whereas they differentially affect the viral life cycle in non-small-cell lung cancer cells Cancer Gene Ther 2006, 13:1105-1114. 10.1038/sj.cgt.7700984 16841078
38. Parker JS Broering TJ Kim J Higgins DE Nibert ML Reovirus core protein mu2 determines the filamentous morphology of viral inclusion bodies by interacting with and stabilizing microtubules J Virol 2002, 76:4483-4496. 155082 11932414 10.1128/JVI.76.9.4483-4496.2002
39. Clarke P Tyler KL Reovirus-induced apoptosis: A minireview Apoptosis 2003, 8:141-150. 10.1023/A:1022966508671 12766474
40. Okada H Mak TW Pathways of apoptotic and non-apoptotic death in tumour cells Nat Rev Cancer 2004, 4:592-603. 10.1038/nrc1412 15286739
41. Cahill DP Lengauer C Yu J Riggins GJ Willson JK Markowitz SD Kinzler KW Vogelstein B Mutations of mitotic checkpoint genes in human cancers Nature 1998, 392:300-303. 10.1038/32688 9521327
42. Yamada HY Gorbsky GJ Spindle checkpoint function and cellular sensitivity to antimitotic drugs Mol Cancer Ther 2006, 5:2963-2969. 2596631 17172401 10.1158/1535-7163.MCT-06-0319
43. Bacus SS Gudkov AV Lowe M Lyass L Yung Y Komarov AP Keyomarsi K Yarden Y Seger R Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53 Oncogene 2001, 20:147-155. 10.1038/ sj.onc.1204062 11313944
44. Deacon K Mistry P Chernoff J Blank JL Patel R p38 Mitogen-activated protein kinase mediates cell death and p21-activated kinase mediates cell survival during chemotherapeutic drug-induced mitotic arrest Mol Biol Cell 2003, 14:2071-2087. 165098 12802076 10.1091/mbc.E02-10-0653
45. Musacchio A Salmon ED The spindle-assembly checkpoint in space and time Nat Rev Mol Cell Biol 2007, 8:379-393. 10.1038/nrm2163 17426725
46. Comins C Spicer J Protheroe A Mukherji D Coffey M Thompson B Harrington K Pandha H A phase I study to evaluate systemic wild-type reovirus (REOLYSIN®) in combination with docetaxel in patients with advanced malignancies International Society for Biological Therapy of Cancer 23rd Annual Meeting Abstracts San Diego, CA. J Immunother 2008:951.
47. Karapanagiotou E Pandha H Hall G Chester J Melcher A De Bono J Gore M Nutting C Harrington K Phase I trial of oncolytic reovirus (Reolysin) in combination with carboplatin/paclitaxel in patients with advanced solid cancers International Society for Biological Therapy of Cancer 23rd Annual Meeting Abstracts San Diego, CA. J Immunother 2008:952.
48. Shoemaker RH The NCI60 human tumour cell line anticancer drug screen Nat Rev Cancer 2006, 6:813-823. 10.1038/nrc1951 16990858
49. Weislow OS Kiser R Fine DL Bader J Shoemaker RH Boyd MR New soluble-formazan assay for HIV-1 cytopathic effects: Application to high-flux screening of synthetic and natural products for AIDS-antiviral activity J Natl Cancer Inst 1989, 81:577-586. 10.1093/jnci/81.8.577 2495366
50. Virgin HWt Bassel-Duby R Fields BN Tyler KL Antibody protects against lethal infection with the neurally spreading reovirus type 3 (Dearing) J Virol 1988, 62:4594-4604. 253571 2460637
51. Borner MM Myers CE Sartor O Sei Y Toko T Trepel JB Schneider E Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3 Cancer Res 1995, 55:2122-2128. 7743512
52. Gonda MA Aaronson SA Ellmore N Zeve VH Nagashima K Ultrastructural studies of surface features of human normal and tumor cells in tissue culture by scanning and transmission electron microscopy J Natl Cancer Inst 1976, 56:245-263. 1255758